Stay updated on SafetyEfficacy SGN-LIV1A+Pembrolizumab in TNBC Clinical Trial
Sign up to get notified when there's something new on the SafetyEfficacy SGN-LIV1A+Pembrolizumab in TNBC Clinical Trial page.

Latest updates to the SafetyEfficacy SGN-LIV1A+Pembrolizumab in TNBC Clinical Trial page
- Check7 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.1%
- Check14 days agoNo Change Detected
- Check21 days agoChange DetectedThe webpage has undergone significant content changes, including the removal of detailed descriptions of a clinical trial for triple-negative breast cancer and the addition of new identifiers and collaborators related to the study.SummaryDifference22%
- Check29 days agoChange DetectedThe page has updated its version from v2.14.3 to v2.14.4, and the date has changed from March 25, 2025, to December 20, 2024.SummaryDifference0.6%
- Check36 days agoNo Change Detected
- Check72 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1%
- Check86 days agoChange DetectedThe web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with a contact email for assistance.SummaryDifference1%
- Check94 days agoChange DetectedThe website has been updated from version 2.14.1 to 2.14.2.SummaryDifference0.1%
Stay in the know with updates to SafetyEfficacy SGN-LIV1A+Pembrolizumab in TNBC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the SafetyEfficacy SGN-LIV1A+Pembrolizumab in TNBC Clinical Trial page.